Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

News

News MOLECULAR PROFILING TO PREDICT SURVIVAL FOR COLON CANCER DEVELOPED IN THE NETHERLANDS Researchers in Leiden University Medical Centre, department of endocrine, gastrointestinal and oncologic surgery, and the Netherlands Cancer Institute have been working collaboratively to develop a method of accurately predicting which patients with colon cancer are more likely to have their disease recur following surgery and who would, therefore, be more likely to benefit from adjuvant chemotherapy. The two centres concentrated their efforts in analysing different expressions of genes in the entire genome of tumour tissues from 121 patients with stage II colon cancer. These patients had not received chemotherapy following surgery to remove the tumour. This exercise managed to identify two distinct groups of patients, both groups having distinct clinical outcomes. European patients with stage II colon cancer are statistically predicted to have an overall 5‐year survival of about 80%. This study confirmed this with the patients in the so‐called ‘good outcome’ group being 90% and of the patients expected to have a ‘poor outcome’ only 40% survived for 5 years post diagnosis. At the present time, no randomized controlled clinical trials had managed to prove the advantage of giving adjuvant chemotherapy to stage II colon http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Loading next page...
 
/lp/wiley/news-0AuDXUKh85

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
© 2008 The Authors
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/j.1365-2354.2008.00926.x
Publisher site
See Article on Publisher Site

Abstract

MOLECULAR PROFILING TO PREDICT SURVIVAL FOR COLON CANCER DEVELOPED IN THE NETHERLANDS Researchers in Leiden University Medical Centre, department of endocrine, gastrointestinal and oncologic surgery, and the Netherlands Cancer Institute have been working collaboratively to develop a method of accurately predicting which patients with colon cancer are more likely to have their disease recur following surgery and who would, therefore, be more likely to benefit from adjuvant chemotherapy. The two centres concentrated their efforts in analysing different expressions of genes in the entire genome of tumour tissues from 121 patients with stage II colon cancer. These patients had not received chemotherapy following surgery to remove the tumour. This exercise managed to identify two distinct groups of patients, both groups having distinct clinical outcomes. European patients with stage II colon cancer are statistically predicted to have an overall 5‐year survival of about 80%. This study confirmed this with the patients in the so‐called ‘good outcome’ group being 90% and of the patients expected to have a ‘poor outcome’ only 40% survived for 5 years post diagnosis. At the present time, no randomized controlled clinical trials had managed to prove the advantage of giving adjuvant chemotherapy to stage II colon

Journal

European Journal of Cancer CareWiley

Published: May 1, 2008

There are no references for this article.